| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 47781-0487-01 | 47781-0487 | Lenalidomide | LENALIDOMIDE | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
| 52658-7777-01 | 52658-7777 | Denileukin diftitox-cxdl | LYMPHIR | 300.0 ug/2mL | Immunotherapy | Cytokine | Interleukin-2 | Intravenous | Mar 1, 2025 | In Use | |
| 00378-1942-21 | 00378-1942 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 7, 2023 | In Use | |
| 66733-0948-23 | 66733-0948 | Cetuximab | Erbitux | 2.0 mg/mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Feb 12, 2004 | In Use | |
| 82705-0002-01 | 82705-0002 | Epcoritamab-bysp | EPKINLY | 4.0 mg/.8mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Subcutaneous | May 19, 2023 | In Use | |
| 00003-3756-14 | 00003-3756 | nivolumab | OPDIVO | 10.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Aug 30, 2021 | In Use | |
| 59572-0775-01 | 59572-0775 | Luspatercept | Reblozyl | 75.0 mg/1 | Immunotherapy | Erythropoiesis-Stimulating Agent | Subcutaneous | Nov 8, 2019 | In Use | ||
| 00173-0821-33 | 00173-0821 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jul 22, 2011 | Aug 31, 2017 | No Longer Used |
| 00074-1044-01 | 00074-1044 | Telisotuzumab Vedotin | EMRELIS | 20.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | c-MET | Intravenous | May 14, 2025 | In Use | |
| 76282-0700-47 | 76282-0700 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jun 10, 2024 | In Use | |
| 59572-0215-13 | 59572-0215 | Thalidomide | Thalomid | 150.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 20, 2007 | In Use | |
| 61755-0056-01 | 61755-0056 | Linvoseltamab-gcpt | LYNOZYFIC | 200.0 mg/10mL | Immunotherapy | Bispecific Antibody | BCMA, CD3 | Intravenous | Jul 2, 2025 | In Use | |
| 00310-4611-50 | 00310-4611 | Durvalumab | Imfinzi | 500.0 mg/10mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | May 1, 2017 | In Use | |
| 31722-0258-01 | 31722-0258 | LENALIDOMIDE | LENALIDOMIDE | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
| 55566-1050-01 | 55566-1050 | Nadofaragene firadenovec-vncg | ADSTILADRIN | 300000000000.0 {VP}/mL | Immunotherapy | Gene Therapy | IFN⍺2b | Intravesical | Sep 5, 2023 | In Use | |
| 50242-0127-01 | 50242-0127 | Glofitamab | Columvi | 10.0 mg/10mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Intravenous | Jun 15, 2023 | In Use | |
| 59651-0344-07 | 59651-0344 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
| 59572-0402-28 | 59572-0402 | Lenalidomide | Revlimid | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 9, 2012 | In Use | |
| 55513-0207-21 | 55513-0207 | Bevacizumab-awwb | MVASI | 400.0 mg/16mL, 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jun 27, 2025 | In Use | |
| 59572-0220-16 | 59572-0220 | Thalidomide | Thalomid | 200.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jun 20, 2003 | In Use | |
| 00378-1936-28 | 00378-1936 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
| 83257-0004-12 | 83257-0004 | Trastuzumab-dkst | OGIVRI | Immunotherapy | Monoclonal Antibody | HER2 | Oct 1, 2023 | In Use | |||
| 47781-0487-77 | 47781-0487 | Lenalidomide | LENALIDOMIDE | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
| 71837-1000-02 | 71837-1000 | Zenocutuzumab | BIZENGRI | 20.0 mg/mL | Immunotherapy | Bispecific Antibody | HER2, HER3 | Intravenous | Dec 16, 2024 | In Use | |
| 59572-0504-21 | 59572-0504 | Pomalidomide | Pomalyst | 4.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 18, 2013 | In Use |
Found 12159 results — Export these results
Home